Most common adverse reactions with Afrezza®
T1D: MOST COMMON ADVERSE REACTIONS (EXCLUDING HYPOGLYCEMIA)1
T2D: MOST COMMON ADVERSE REACTIONS (EXCLUDING HYPOGLYCEMIA)1
These adverse reactions, which exclude hypoglycemia, were not present at baseline, occurred more commonly on Afrezza than placebo and/or comparator, and occurred in at least 2% of patients treated with Afrezza in the pool of active-controlled and placebo-controlled trials in patients with T1D and T2D, respectively.1
INCIDENCE OF COUGH IN POOLED SAFETY POPULATION2
- 94% of cough episodes were characterized as intermittent or single defined episodes2
- Cough was generally mild, dry, occurred within 10 minutes of inhalation, was transient, and declined with continued use2
Afrezza has been studied
in >3,000 patients1
The following may help patients who
develop a cough while taking Afrezza
Use Afrezza at room temperature1*
Have a sip of water before and after inhaling1
*Before an Afrezza cartridge is put in an inhaler, it must be at room temperature for 10 minutes.
Actual Afrezza User
References: 1. Afrezza (insulin human) Inhalation Powder Prescribing Information. MannKind Corporation. 2. Data on file. MannKind Corporation.